Literature DB >> 27000510

Validity of Current Stereotactic Body Radiation Therapy Dose Constraints for Aorta and Major Vessels.

Jinyu Xue1, Gregory Kubicek2, Ashish Patel2, Benjamin Goldsmith2, Sucha O Asbell2, Tamara A LaCouture2.   

Abstract

Understanding dose constraints for critical structures in stereotactic body radiation therapy (SBRT) is essential to generate a plan for optimal efficacy and safety. Published dose constraints are derived by a variety of methods, including crude statistics, actuarial analysis, modeling, and simple biologically effective dose (BED) conversion. Many dose constraints reported in the literature are not consistent with each other, secondary to differences in clinical and dosimetric parameters. Application of a dose constraint without discriminating the variation of all the factors involved may result in suboptimal treatment. This issue of Seminars in Radiation Oncology validates dose tolerance limits for 10 critical anatomic structures based on dose response modeling of clinical outcomes data to include detailed dose-volume metrics. This article presents a logistic dose-response model for aorta and major vessels based on 238 cases from the literature in addition to 387 cases from MD Anderson Cancer Center at Cooper University Hospital, for a total of 625 cases. The Radiation Therapy Oncology Group (RTOG) 0813 dose-tolerance limit of Dmax = 52.5Gy in 5 fractions was found to have a 1.2% risk of grade 3-5 toxicity, and the Timmerman 2008 limit of Dmax = 45Gy in 3 fractions had 2.3% risk. From the model, the 1% and 2% risk levels for D4cc, D1cc, and D0.5cc are also provided in 1-5 fractions, in the form of a dose-volume histogram (DVH) Risk Map.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 27000510     DOI: 10.1016/j.semradonc.2015.11.001

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  10 in total

Review 1.  GOECP/SEOR radiotheraphy guidelines for non-small-cell lung cancer.

Authors:  Núria Rodríguez De Dios; Arturo Navarro-Martin; Cristina Cigarral; Rodolfo Chicas-Sett; Rafael García; Virginia Garcia; Jose Antonio Gonzalez; Susana Gonzalo; Mauricio Murcia-Mejía; Rogelio Robaina; Amalia Sotoca; Carmen Vallejo; German Valtueña; Felipe Couñago
Journal:  World J Clin Oncol       Date:  2022-04-24

Review 2.  Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer.

Authors:  Jamie E Chaft; Andreas Rimner; Walter Weder; Christopher G Azzoli; Mark G Kris; Tina Cascone
Journal:  Nat Rev Clin Oncol       Date:  2021-04-28       Impact factor: 65.011

Review 3.  Doses, fractionations, constraints for stereotactic radiotherapy.

Authors:  Simona Borghesi; Cynthia Aristei; Francesco Marampon
Journal:  Rep Pract Oncol Radiother       Date:  2022-03-22

4.  Is pulmonary artery a dose-limiting organ at risk in non-small cell lung cancer patients treated with definitive radiotherapy?

Authors:  Jie-Tao Ma; Li Sun; Xin Sun; Zhi-Cheng Xiong; Yang Liu; Shu-Ling Zhang; Le-Tian Huang; Cheng-Bo Han
Journal:  Radiat Oncol       Date:  2017-02-01       Impact factor: 3.481

Review 5.  Radiobiological Optimization in Lung Stereotactic Body Radiation Therapy: Are We Ready to Apply Radiobiological Models?

Authors:  Marco D'Andrea; Silvia Strolin; Sara Ungania; Alessandra Cacciatore; Vicente Bruzzaniti; Raffaella Marconi; Marcello Benassi; Lidia Strigari
Journal:  Front Oncol       Date:  2018-01-08       Impact factor: 6.244

Review 6.  Stereotactic spine radiosurgery: Review of safety and efficacy with respect to dose and fractionation.

Authors:  Michael Huo; Arjun Sahgal; David Pryor; Kristin Redmond; Simon Lo; Matthew Foote
Journal:  Surg Neurol Int       Date:  2017-02-20

7.  Potential Clinical Significance of Overall Targeting Accuracy and Motion Management in the Treatment of Tumors That Move With Respiration: Lessons Learnt From a Quarter Century of Stereotactic Body Radiotherapy From Dose Response Models.

Authors:  Anand Mahadevan; Bahman Emami; Jimm Grimm; Lawrence R Kleinberg; Kristin J Redmond; James S Welsh; Robert Rostock; Eric Kemmerer; Kenneth M Forster; Jason Stanford; Sunjay Shah; Sucha O Asbell; Tamara A LaCouture; Carla Scofield; Ian Butterwick; Jinyu Xue; Alexander Muacevic; John R Adler
Journal:  Front Oncol       Date:  2021-02-09       Impact factor: 6.244

8.  Influence of target dose heterogeneity on dose sparing of normal tissue in peripheral lung tumor stereotactic body radiation therapy.

Authors:  Zhigong Wei; Xingchen Peng; Yan Wang; Lianlian Yang; Ling He; Zheran Liu; Jingjing Wang; Xiaoli Mu; Ruidan Li; Jianghong Xiao
Journal:  Radiat Oncol       Date:  2021-08-30       Impact factor: 3.481

Review 9.  Stereotactic radiotherapy for lung oligometastases.

Authors:  Lorenzo Falcinelli; Claudia Menichelli; Franco Casamassima; Cynthia Aristei; Simona Borghesi; Gianluca Ingrosso; Lorena Draghini; Angiolo Tagliagambe; Serena Badellino; Michela Buglione di Monale E Bastia
Journal:  Rep Pract Oncol Radiother       Date:  2022-03-22

10.  Estimating the tolerance of brachial plexus to hypofractionated stereotactic body radiotherapy: a modelling-based approach from clinical experience.

Authors:  Irina Kapitanova; Sharmi Biswas; Sabrina Divekar; Eric J Kemmerer; Robert A Rostock; Kenneth M Forster; Rachel J Grimm; Carla J Scofield; Jimm Grimm; Bahman Emami; Anand Mahadevan
Journal:  Radiat Oncol       Date:  2021-06-07       Impact factor: 3.481

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.